Company: SCLXW
Filing Date: 2025-05-07
Form Type: POS AM
Source: 0001193125-25-115054
Chunk: 192

Company: Scilex Holding Co
Filing Date: 2025-05-07
Form: POS AM
Chunk 192
---
 3,386 |
| Total indebtedness                                                                                                           |     | $            | 45,416 |     | $            | 128,853 |

The Oramed Note As of December 31, 2024, the fair value of the Oramed Note outstanding was $12.2 million pursuant to the Scilex-Oramed SPA (see Note 7 titled “ Debt”to our consolidated financial statements included elsewhere in this prospectus for additional information). Convertible Debentures We fully repaid the Convertible Debentures in March 2024 (see Note 7 titled “ Debt”to our consolidated financial statements included elsewhere in this prospectus for additional information). Tranche B Notes As of December 31, 2024, the fair value of the Tranche B Notes outstanding was $23.6 million pursuant to the Tranche B Securities Purchase Agreement (see Note 7 titled “ Debt” to our consolidated financial statements included elsewhere in this prospectus for additional information). Purchased Revenue Liability As of December 31, 2024, the fair value of the purchased revenue liability was $6.8 million pursuant to the ZTlido Royalty Purchase Agreement (see Note 7 titled “ Debt” to our consolidated financial statements included elsewhere in this prospectus for additional information). Revolving Facility We fully repaid the Revolving Facility in October 2024 (see Note 7 titled “ Debt”to our consolidated financial statements included elsewhere in this prospectus for additional information). Deferred Consideration As of December 31, 2024, we have $2.9 million of deferred consideration related to minimum royalty payments that were included in the initial measurement of consideration transferred for the GLOPERBA license. Deferred consideration minimum royalty payments began in July 2023. 122

ZTlido, ELYXYB and GLOPERBA Royalties

In February 2013, Scilex Pharma became a party to the Product Development Agreement with Itochu and Oishi (together, the “Developers”), pursuant to which the Developers will manufacture and supply lidocaine tape products, including ZTlido and SP-103, for Scilex Pharma. Pursuant to the Product Development Agreement, Scilex Pharma is required to make aggregate royalty payments between 25% and 35% to the Developers based on net profits. During each of the years ended December 31, 2024 and 2023, Scilex Pharma made royalty payments in the